Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 1-2, 2000, Pages 3-18

  Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Anandamide; Cannabinoids; CB1 receptor; Fatty acid amide hydrolase; Gastrointestinal; N Arachidonylphosphatidylethanolamine; Reproduction

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMIDASE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; LUTEINIZING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROSTAGLANDIN DERIVATIVE; RECEPTOR SUBTYPE; TETRAHYDROCANNABINOL;

ARACHIDONIC ACID METABOLISM; BINDING AFFINITY; BRAIN; CALCIUM CELL LEVEL; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FERTILIZATION; FOOD INTAKE; GASTROINTESTINAL MOTILITY; HUMAN; MOUSE; NERVE CELL; NEUROTRANSMISSION; NIDATION; NONHUMAN; PREGNANCY; RABBIT; RAT; REVIEW; STILLBIRTH; TESTIS;

EID: 0033998951     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00051-4     Document Type: Article

References (130)

1. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 86:1964;1646-1647.
2. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1984;1803-1810.
3. Devane W.A., Dysarz F.A., Johnson M.R., et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:1988;606-613.
4. Matsuda L.A., Lolait S.J., Brownstein M.J., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
5. Gerard C.M., Mollereau C., Vassart G., et al. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 279:1991;129-134.
6. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
8. Sugiura T., Kondo S., Sukagawa A., et al. 2-Arachidonoylglycerol a possible endogenous cannabinoid receptor ligand in brain . Biochem Biophys Res Comm. 215:1995;89-92.
9. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
10. 2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun. 229:1996;58-64.
11. Sugiura T., Kodaka T., Nakane S., et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem. 274:1999;2794-2801.
12. Varga K., Wagner J.A., Bridgen D.T., et al. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
13. Bachur N.R., Masek K., Melmon K.L., et al. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem. 240:1965;1019-1024.
14. Schmid H.H.O., Schmid P.C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog Lipid Res. 29:1990;1-43.
15. Schmid H.H.O., Schmid P.C., Natarajan V. The N-acylation-phosphodiesterase pathway and cell signaling. Chem Physics Lipids. 80:1996;133-142.
16. Di Marzo V., Fontana A., Cadas H., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
17. Sugiura T., Kondo S., Sukagawa A., et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Eur J Biochem. 240:1996;53-62.
18. Sasaki T., Chang M.C.J. N-Arachidonylethanolamine (anandamide) formation from N-arachidonylphosphtidylethanolamine in rat brain membranes. Life Sci. 61:1997;1803-1810.
19. 2+-dependent transacylase and phosphodiesterase activities . Biochem Biophys Res Comm. 218:1996;113-117.
20. Kondo S., Suguira T., Kodaka T., et al. Accumulation of various N-acylethanolamines including N-arachdionylethanolamine (anandamide) in cadmium chloride-administered rat testes. Arch Biochem Biophys. 354:1998;303-310.
21. Schmid P.C., Reddy P.V., Natarajan V., et al. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem. 258:1983;9302-9306.
22. Natarajan V., Schmid P., Reddy P., et al. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem. 42:1984;1613-1619.
23. Di Marzo V., De Petrocellis L., Sepe N., et al. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J. 316:1996;977-984.
24. Liscovitch M., Chalifa-Caspi V. Enzymology of mammalian phospholipases D in vitro studies . Chem Phys Lipids. 80:1996;37-44.
25. Petersen G., Hansen H.S. N-Acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate. FEBS Lett. 455:1999;41-44.
26. Hansen H.S., Lauritzen L., Strand A.M., et al. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. J Biol Chem. 270:1995;23823-23827.
27. Cadas H., Gaillet S., Beltramo M., et al. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci. 16:1996;3934-3942.
28. Hansen H.S., Lauritzen L., Strand A.M., et al. Characterization of glutamate-induced formation of N- acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J Neurochem. 69:1997;753-761.
29. Hansen H.S., Lauritzen L., Moesgaard B., et al. Formation of N-acyl-phosphatidylethanolamines and N-acylethanolamines proposed role in neurotoxicity . Biochem Pharmacol. 55:1998;719-725.
30. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonyl phosphatidylethanolamine, in rat brain. J Neurosci. 17:1997;1226-1242.
31. Yang H.Y., Karoum F., Felder C., et al. GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J Neurochem. 72:1999;1959-1968.
32. Bisogno T., Berrendero F., Ambrosino G., et al. Brain regional distribution of endocannabinoids implications for their biosynthesis and biological function . Biochem Biophys Res Comm. 256:1999;377-380.
33. Schmid P.C., Schwindenhammer D., Krebsbach R.J., et al. Alternative pathways of anandamide biosynthesis in rat testes. Chem Phys Lipids. 92:1998;27-35.
34. Kuwae T., Schmid P.C., Schmid H.H.O. Alterations of fatty acyl turnover in macrophage glycerolipids induced by stimulation. Evidence for enhanced recycling of arachidonic acid. Biochim Biophys Acta. 1344:1997;74-86.
35. Blank M.L., Cress E.A., Robinson M., et al. Metabolism of unique diarachidonoyl and linoleoylarachidonoyl species of ethanolamine and choline phosphoglycerides in rat testes. Biochim Biophys Acta. 833:1985;366-371.
36. Di Marzo V., De Petrocellis L., Sugiura T., et al. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide, and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun. 227:1996;281-288.
37. Colodzin M., Bachur N.R., Weissbach H., et al. Enzymatic formation of fatty acid amides. Biochem Biophys Res Comm. 10:1963;165-170.
38. Bachur N.R., Udenfriend S. Microsomal synthesis of fatty acid amides. J Biol Chem. 241:1965;1308-1313.
39. Deutsch D., Chin S. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:1993;791-796.
40. Kruszka K., Gross R. The ATP- and CoA-independent synthesis of anandamide, a cannabinoid receptor agonist. J Biol Chem. 269:1994;14345-14348.
41. Devane W., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci. 91:1994;6698-6701.
42. Arreaza G., Devane W., Omeir R.L., et al. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci Letts. 234:1997;59-62.
43. Kurahashi Y., Ueda N., Suzuki H., et al. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem Biophys Res Commun. 237:1997;512-515.
44. Pestonjamasp V.K., Burstein S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta. 1394:1998;249-260.
45. 2+- dependent and -independent mechanisms . FEBS Lett. 429:1998;152-156.
46. Bisogno T., Sepe N., Melck D., et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J. 322:1997;671-677.
47. Sugiura T., Kodaka T., Nakane S., et al. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun. 243:1998;838-843.
48. Bisogno T., Melck D., De Petrocellis L., et al. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J Neurochem. 72:1999;2113-2119.
49. Schmid P., Zuzarte-Augustin M., Schmid H. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem. 260:1985;14145-14149.
50. Maccarrone M., van der Stelt M., Rossi A., et al. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem. 273:1998;32332-32339.
51. Hillard C., Wilkison D., Edgemond W., et al. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta. 1257:1995;249-256.
52. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem. 270:1995;6030-6035.
53. Maurelli S., Bisogno T., De Petrocellis L., et al. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Letts. 377:1995;82-86.
54. Cravatt B., Prospero-Garcia O., Siuzdak G., et al. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
55. Cravatt B., Giang D., Mayfield S., et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 384:1996;84-87.
56. Di Marzo V., Bisogno T., Sugiura T., et al. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells connections with anandamide . Biochem J. 331:1998;15-19.
57. Goparaju S.K., Ueda N., Yamaguchi H., et al. Anandamide amidohydrolase reacting with 2-arachidonylglycerol, another cannabinoid receptor ligand. FEBS Letts. 422:1998;69-73.
58. Di Marzo V., Bisogno T., De Petrocellis L., et al. Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 264:1999;258-267.
59. Goparaju S.K., Ueda N., Taniguchi K., et al. Enzymes of porcine brain hydrolyzing 2-arachidonylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol. 57:1999;417-423.
60. Patricelli M.P., Lashuel H.A., Giang D.K., et al. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase identification of the transmembrane domain as a site for oligomerization . Biochemistry. 37:1998;15177-15187.
61. Omeir R, Cravatt B, Deutsch DG. Identification of residues involved in fatty acid amide hydrolase catalytic activity. International Cannabinoid Research Society 1998 Symposium on the Cannabinoids 1998:15.
62. Ueda N., Kurahashi Y., Yamamoto S., et al. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem. 270:1995;23823-23827.
63. Deutsch D.G., Omeir R., Arreaza G., et al. Methyl arachidonyl fluorophosphonate a potent irreversible inhibitor of anandamide amidase . Biochem Pharmacol. 53:1997;255-260.
64. Goparaju S.K., Kurahashi Y., Suzuki H., et al. Anandamide amidohydrolase of porcine brain cDNA cloning, functional expression, and site-directed mutagenesis . Biochim Biophys Acta. 1441:1999;77-84.
65. Patricelli M.P., Lovato M.A., Cravatt B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase evidence for a family of serine hydrolases with distinct catalytic properties . Biochemistry. 38:1999;9804-9812.
66. Omeir R.L., Arreaza G., Deutsch D.G. Identification of two serine residues involved in catalysis by fatty acid amide hydrolase. Biochem Biophys Res Commun. 264:1999;316-320.
67. Egertova M., Giang D.K., Cravatt B.F., et al. A new perspective on cannabinoid signaling complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain . Proc R Soc Lond B Biol Sci. 265:1998;2081-2085.
68. Tsou K., Nogueron M.I., Muthian S., et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett. 254:1998;137-140.
69. Tsou K., Brown S., Sanudo-Pena M., et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
70. Kitahama K., Arai R., Maeda T., et al. Demonstration of monoamine oxidase type B in serotonergic and type A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique. Neurosci Lett. 71:1986;19-24.
71. Hillard C.J., Edgemond W.S., Jarrahian A., et al. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem. 69:1997;631-638.
72. Bisogno T., Maurelli S., Melck D., et al. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 272:1997;3315-3323.
73. Piomelli D., Beltramo M., Glasnapp S., et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A. 96:1999;5802-5807.
74. Beltramo M., Stella N., Calignano A., et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
75. Calignano A, La Rana G, A. G, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81.
76. Kanai N., Lu R., Satriano J.A., et al. Identification and characterization of a prostaglandin transporter. Science. 268:1995;866-869.
77. Houston D.B., Howlett A.C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol Pharmacol. 43:1993;17-22.
78. 35S]thio]-triphosphate binding. Proc Natl Acad Sci. 92:1995;7242-7246.
79. Kearn C.S., Greenberg M.J., DiCamelli R., et al. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem. 72:1999;2379-2387.
80. Pacheco M.A., Ward S.J., Childers S.R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110.
81. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 27:1985;429-436.
82. Felder C.C., Veluz J.S., Williams H.L., et al. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol. 42:1992;838-845.
83. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci. 89:1992;3825-3829.
84. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 106:1992;231-232.
85. Deadwyler S.A., Hampson R.E., Mu J., et al. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther. 273:1995;734-743.
86. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Letts. 186:1995;91-94.
87. Sugiura T., Kodaka T., Kondo S., et al. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun. 233:1997;207-210.
88. Gruol D.L., Netzeband J.G., Qiu Z., et al. Cannabinoids and interleukin-6 (IL-6) enhance the response to NMDA in developing CNS neurons. Adv Exp Med Biol. 402:1996;111-117.
89. Deutsch D., Goligorsky M.S., Schmid P.C., et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 100:1997;1538-1546.
90. Bouaboula M., Poinot-Chazel C., Bourrie B., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J. 312:1995;637-641.
91. Bouaboula M., Bourrie B., Rinaldi-Carmona M., et al. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem. 270:1995;13973-13980.
92. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol. 54:1998;834-843.
93. i-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett. 449:1999;61-65.
94. Bouaboula M., Perrachon S., Milligan L., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem. 272:1997;22330-22339.
95. Hillard C., Campbell W. Biochemistry and pharmacology of arachidonylethanolamine, a putative endogenous cannabinoid. J Lipid Res. 38:1997;2383-2398.
96. Vogel Z., Barg J., Levy R., et al. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem. 61:1993;352-355.
97. Childers S., Sexton T., Roy M. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol. 47:1994;711-715.
98. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 44:1993;498-503.
99. Felder C.C., Joyce K.E., Briley E.M., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-450.
100. 2+ channel current. Am J Physiol. 276:1999;H2085-H2093.
101. 35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59:1996;659-668.
102. Burkey T.H., Quock R.M., Consroe P., et al. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol. 336:1997;295-298.
103. 9-THC on pregnancy and offspring in rats. Neurobev Toxicol Teratol. 6:1984;29-32.
104. Rosenkrantz H., Grant R.J., Fleischman R.W., et al. Marijuana-induced embryotoxicity in the rabbit. Fund Appl Toxicol. 7:1986;236-243.
105. Wenger T., Fragkakis G., Giannikou P., et al. Effects of anandamide on gestation in pregnant rats. Life Sci. 60:1997;2361-2371.
106. Fride E., Mechoulam R. Developmental aspects of anandamide ontogeny of response and prenatal exposure . Eur J Pharmacol. 296:1996;347-350.
107. Schuel H., Goldstein E., Mechoulam R., et al. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci. 91:1994;7678-7682.
108. Schuel H., Schuel R., Zimmerman A.M., et al. Cannabinoids reduce fertility of sea urchin sperm. Biochem Cell Biol. 65:1987;130-136.
109. Pertwee R., Griffin G., Hanus L., et al. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. J Pharmacol Exp Ther. 270:1994;219-227.
110. Pertwee R.G., Joe-Adigwe G., Hawksworth G.M. Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens. Eur J Pharmacol. 296:1996;169-172.
111. Das SK, Paria BC, Chakraborty I, et al. Cannabinoid ligand-receptor signaling in the mouse uterus. Eur J Pharmacol 1995;278:279-83.
112. Paria B.C., Das S.K., Dey S.K. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci. 92:1995;9460-9464.
113. Paria B.C., Ma W., Andrenyak D.M., et al. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol Reprod. 58:1998;1490-1495.
114. Yang Z.M., Paria B.C., Dey S.K. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development. Biol Reprod. 55:1996;756-761.
115. Schmid P.C., Paria B.C., Krebsbach R.J., et al. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A. 94:1997;4188-4192.
116. Herkenham M., Lynn A.B., Little M.D., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 87:1990;1932-1936.
117. 9-tetrahydrocannabinol in rat isolated stomach. Eur J Pharmacol. 65:1980;317-318.
118. Shook J.E., Burks T.F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther. 249:1989;444-449.
119. Varga K., Lake K., Martin B.R., et al. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 278:1995;279-283.
120. 9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol. 371:1999;187-196.
121. 9-tetrahydrocannabinol. Behav Biol. 20:1977;104-110.
122. Mattes R.D., Engelman K., Shaw L.M., et al. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 49:1995;187-195.
123. Williams C.M., Kirkham T.C. Anandamide induces overeating mediation by central cannabinoid (CB1) receptors . Psychopharmacology (Berl). 143:1999;315-317.
124. Arnone M., Maruani J., Chaperon F., et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 132:1997;104-106.
125. Calignano A., La Rana G., Makriyannis A., et al. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol. 340:1997;R7-R8.
126. Coutts A.A., Pertwee R.G. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Brit J Pharmacol. 121:1997;1557-1566.
127. Griffin G., Fernando S.R., Ross R.A., et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol. 339:1997;53-61.
128. Ross R.A., Brockie H.C., Fernando S.R., et al. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br J Pharmacol. 125:1998;1345-1351.
129. Heinemann A., Shahbazian A., Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology. 38:1999;1289-1297.
130. Pertwee R.G., Fernando S.R., Nash J.E., et al. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol. 118:1996;2199-2205.